NASDAQ$ULBI

Ultralife Corporation · Q2 2020 earnings

Q2 2020 earnings · · Investor relations

Briefing

Reported operating income of $2.3 million on revenue of $28.6 million.

Ultralife Corporation reported a decrease in revenue and operating income for the second quarter of 2020 compared to the same period in 2019. However, the company's adjusted earnings per share of $0.13 reflects the benefits of end-market diversity and a resilient business model despite business disruptions caused by the pandemic.

  • Battery and Energy Products' medical sales increased 72% year-over-year.
  • Government/defense sales increased 50% year-over-year.
  • Commercial sales increased 7.5% while government/defense sales decreased 13.7% from the 2019 period.
  • These orders were completed in the second quarter of 2020.

Headline financials

Total Revenue

$28.6M

Previous: $29.4M-2.8%
EPS (adj)

$0.13

Previous: $0.18-27.8%
Gross Margin

27.9%

Previous: 30.2%-7.6%
Adjusted EBITDA

$3.3M

Previous: $4.1M-19.5%
Capital Expenditures

-$1.53M

Previous: -$3.79M+59.6%
Free Cash Flow

$125K

Previous: -$1.54M+108.1%
Net Income

$1.66M

Previous: $2.26M-26.5%
Operating Income

$2.29M

Previous: $3.04M-24.6%
Gross Profit

$7.96M

Previous: $8.87M-10.2%
Cash & Equivalents

$8.3M

Previous: $6.53M+27.1%
Total Assets

$138M

Previous: $142M-2.9%
Stock-Based Comp

$304K

Previous: $175K+73.7%

Revenue & EPS history

Ultralife · Revenue · Quarterly

$28.6M

Q2 2020-2.8%vs Q2 2019
Beat estimate in 0 of 1 quarters(0%)
ActualEstimate

Revenue by segment

Ultralife · $28.5M total across 2 segments · Q2 2020

  • Battery & Energy Products
    $24M+18.2%
  • Communications Systems
    $4.5M-50.5%

Forward guidance

Ultralife's second quarter adjusted earnings per share of $0.13 cents reflects the benefits of our end-market diversity and resilient business model in the face of continued business disruptions caused by the pandemic.

Tailwinds

  • Ultralife’s second quarter adjusted earnings per share of $0.13 cents reflects the benefits of our end-market diversity and resilient business model in the face of continued business disruptions caused by the pandemic
  • Battery and Energy Products’ medical sales increased 72% year over year
  • government/defense sales increased 50% year over year
  • SWE contribution nearly offset Communications Systems sales decrease
  • Ultralife is durably positioned both to sustain profitability and positive cash flow/liquidity through a period of economic weakness and to execute on initiatives to drive future growth opportunities.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2020

Historical avgQ2 2020

+0.1%

Avg return

Earnings day

+1.7%

Avg return

5 days after

+5.4%

Avg return

30 days after

46%

30 / 65 earnings

Positive

+56.6%

Q2 2023

Best reaction

-26.7%

Q2 2012

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-14.3%-16.4%-4.6%
Q4 2025+8.3%+22.9%+28.5%
Q3 2025-9.0%-5.4%+4.7%
Q1 2025+2.9%+13.1%+57.8%
Q4 2024-6.1%-16.0%-18.2%
Q3 2024-14.3%-16.5%-18.3%
Q2 2024-3.1%-4.1%-1.8%
Q1 2024+30.5%+34.0%+29.4%
Q4 2023+16.5%+11.6%+6.6%
Q3 2023-22.3%-19.3%-18.2%
Q2 2023+56.6%+70.8%+87.4%
Q1 2023+3.6%-1.2%+4.9%
Q4 2022+0.5%-3.2%-0.2%
Q3 2022-4.6%-7.1%-15.4%
Q2 2022-4.1%-1.9%+8.8%
Q1 2022+6.4%+3.9%+7.1%
Q4 2021-7.4%-9.1%+0.9%
Q3 2021-9.3%-7.4%-19.9%
Q2 2021-6.3%-4.8%-5.3%
Q1 2021-1.4%-3.5%+14.0%
Q4 2020+8.2%+24.6%+11.9%
Q3 2020-9.8%-6.5%+20.1%
Q2 2020+1.7%+1.0%-9.7%
Q1 2020+7.6%+19.7%+19.3%
Q4 2019+11.4%+12.7%+0.0%
Q3 2019-7.1%-5.5%-6.4%
Q2 2019+6.0%-1.8%-1.8%
Q1 2019-18.1%-23.2%-30.0%
Q4 2018+4.1%+12.9%+26.1%
Q3 2018+10.9%+9.7%+8.4%
Q2 2018-3.5%-1.0%-13.5%
Q1 2018+3.3%+0.0%+12.1%
Q4 2017+7.6%+8.3%+19.7%
Q3 2017-14.3%-12.2%-12.9%
Q2 2017-2.2%-4.3%-6.5%
Q1 2017+7.2%+6.3%+20.7%
Q4 2016-1.0%+6.9%+8.8%
Q3 2016-7.8%-8.9%+6.7%
Q2 2016-7.6%-13.8%-11.0%
Q1 2016-11.0%
Q4 2015-4.5%
Q3 2015+5.3%
Q2 2015+0.0%
Q1 2015+1.5%
Q4 2014+9.7%
Q3 2014+5.7%
Q2 2014-8.3%
Q1 2014+7.2%
Q4 2013-5.2%
Q3 2013-4.5%
Q2 2013-0.3%
Q1 2013+1.8%
Q4 2012+11.2%
Q3 2012+5.9%
Q2 2012-26.7%
Q1 2011+0.5%
Q1 2012-1.0%
Q4 2011+0.6%
Q4 2009+0.6%
Q3 2011-3.0%
Q3 2010-3.0%
Q4 2010-0.2%
Q2 2010-0.2%
Q2 2011-0.2%
Q1 2010+4.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro